文献速递儿科影像腹部US

儿童肝脏CEUS标准:良恶性局灶性病变鉴别的前瞻性初步研究

Development of a pediatric liver CEUS criterion to classify benign and malignant liver lesions in pediatric patients: a pilot study.
PubMed 文献 · Eur Radiol · 2021-03-05

该回顾性研究分析了130例儿童局灶性肝脏病变的CEUS特征,开发了儿童肝脏CEUS-1至CEUS-5分类标准。以<5岁患者高增强伴廓清或早期廓清(≤45s)预测肝母细胞瘤的敏感度和特异度分别为90.7%和93.6%;周边不连续球状高增强诊断血管瘤的敏感度和特异度分别为84.6%和100.0%。CEUS-1至CEUS-5类恶性率分别为0.0%、0.0%、5.6%、50.0%和96.1%。

要点

  • 儿童肝脏CEUS分类标准CEUS-1至CEUS-5可区分良恶性病变,尤其有助于鉴别肝母细胞瘤与血管瘤。
  • 年龄<5岁患者出现高增强伴廓清,或早期廓清(≤45s),提示肝母细胞瘤。
  • 周边不连续球状高增强提示血管瘤,特异度达100.0%。

关键影像表现/征象

  • 以<5岁患者出现高增强伴廓清或早期廓清(≤45s)预测肝母细胞瘤,敏感度90.7%(95%CI:77.9%,97.4%),特异度93.6%(95%CI:84.3%,98.2%)。
  • 周边不连续球状高增强诊断血管瘤,敏感度84.6%(95%CI:65.1%,95.6%),特异度100%(95%CI:95.4%,100.0%)。
  • CEUS-1至CEUS-5类恶性率分别为0.0%、0.0%、5.6%、50.0%、96.1%。
  • CEUS-3、CEUS-4、CEUS-5类中肝母细胞瘤发生率分别为5.6%、16.7%、67.5%。

诊断标准与关键数值

  • 儿童肝脏CEUS分类标准分为CEUS-1至CEUS-5类,恶性率分别为0.0%、0.0%、5.6%、50.0%、96.1%。
  • 以<5岁患者高增强伴廓清或早期廓清(≤45s)预测肝母细胞瘤,敏感度90.7%(95%CI:77.9%,97.4%),特异度93.6%(95%CI:84.3%,98.2%)。
  • 以周边不连续球状高增强诊断血管瘤,敏感度84.6%(95%CI:65.1%,95.6%),特异度100%(95%CI:95.4%,100.0%)。

临床应用与阅片要点

  • 对儿童肝脏局灶性病变,可依据年龄、增强模式及廓清时间(尤其≤45s)应用CEUS分类标准辅助鉴别肝母细胞瘤与血管瘤。
  • CEUS-4类和CEUS-5类恶性率较高(分别为50.0%和96.1%),CEUS-1类和CEUS-2类恶性率均为0.0%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To analyze the contrast-enhanced ultrasound (CEUS) characteristics of pediatric patients with focal liver lesions (FLLs) and develop a pediatric liver CEUS criterion to improve the diagnostic performance of CEUS in differentiating pediatric benign and malignant liver lesions.

METHODS: Between March 2011 and May 2020, patients < 18 years who underwent CEUS were retrospectively evaluated. The CEUS characteristics of FLLs were analyzed. A pediatric liver CEUS criterion categorized as CEUS-1 to CEUS-5 was developed. The diagnostic performance of the criterion (i.e., sensitivity, specificity, PPV, and NPV) was assessed. Chi-square and Mann-Whitney tests were used.

RESULTS: After exclusion, the study included 130 lesions (mean diameter, 7.1 cm; range, 0.8-17.0 cm) from 130 patients (mean age, 36.0 months; range, 0.03-204.0 months; 74 boys). Hyperenhancement with washout in patients < 5 years or with early washout (≤ 45 s) was used to predict hepatoblastoma, with a sensitivity and specificity of 90.7% (95% confidence interval [CI]: 77.9%, 97.4%) and 93.6% (95% CI: 84.3%, 98.2%), respectively. Peripheral discontinuous globular hyperenhancement was used to diagnose hemangioma, with a sensitivity and specificity of 84.6% (95% CI: 65.1%, 95.6%) and 100% (95% CI: 95.4%, 100.0%), respectively. The rates of malignancies within the pediatric liver CEUS-1, CEUS-2, CEUS-3, CEUS-4, and CEUS-5 categories were 0.0%, 0.0%, 5.6%, 50.0%, and 96.1%, respectively. Besides, the incidences of hepatoblastoma in pediatric liver CEUS-3, CEUS-4, and CEUS-5 were 5.6%, 16.7%, and 67.5%, respectively.

CONCLUSIONS: The pediatric liver CEUS criterion is useful in differentiating benign focal liver lesions from malignancies, especially hepatoblastoma from hemangioma.

KEY POINTS: • Hyperenhancement with washout in patients <v5 years or with early washout (≤ 45 s) were used to predict hepatoblastoma, with a sensitivity and specificity of 90.7% and 93.6%. • Peripheral discontinuous globular hyperenhancement was used to diagnose hemangioma, with a sensitivity and specificity of 84.6% and 100.0%. • The rates of malignancies within the pediatric liver CEUS-1, CEUS -2, CEUS-3, CEUS-4, and CEUS-5 categories were 0.0%, 0.0%, 5.6%, 50.0%, and 96.1%, respectively.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang G, Xie X, Chen H, et al. Development of a pediatric liver CEUS criterion to classify benign and malignant liver lesions in pediatric patients: a pilot study. Eur Radiol. 2021. PMID: 33666698. doi:10.1007/s00330-021-07784-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。